Maze Therapeutics, Inc. (MAZE) - What Are Brokerages Saying About This Stock?

Key Points

• Analysts remain broadly bullish: Fourteen brokerages rate Maze Therapeutics “Buy” overall, including ten buy and three strong-buy ratings versus one sell. The average 12-month price target is $64.45, with recent targets ranging from $46 to $110.
• MAZE opened at $31.01, well below its 52-week high of $53.65, while analysts expect a full-year loss of approximately $2.70 per share. The company’s latest quarterly loss of $0.76 per share matched consensus estimates.
• Institutional ownership increased as several major investors, including ARCH Venture Management, Alphabet and TRV GP IV, established or expanded positions during the second quarter. However, insiders have sold approximately $5.15 million worth of shares over the past three months.

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been assigned a consensus recommendation of "Buy" from the fourteen brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and three have assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $64.45.

MAZE has been the subject of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $110.00 price target on shares of Maze Therapeutics in a research report on Thursday, September 24th. BTIG Research restated a "buy" rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Tuesday, September 22nd. Wall Street Zen cut shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Maze Therapeutics in a research note on Monday, September 21st. Finally, Canaccord Genuity Group began coverage on Maze Therapeutics in a report on Monday, October 19th. They set a "buy" rating and a $75.00 price target on the stock.

Maze Therapeutics Price Performance

NASDAQ MAZE opened at $31.01 on Monday. The business's 50-day moving average is $27.17 and its 200 day moving average is $27.09. The stock has a market capitalization of $1.72 billion, a PE ratio of -12.31 and a beta of 2.16. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. Maze Therapeutics has a 1 year low of $21.95 and a 1 year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.76). Sell-side analysts forecast that Maze Therapeutics will post -2.70 earnings per share for the current year.

Insider Transactions at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 16,141 shares of the business's stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $26.93, for a total transaction of $434,677.13. Following the completion of the sale, the chief marketing officer directly owned 16,141 shares in the company, valued at $434,677.13. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Courtney Phillips sold 2,012 shares of the company's stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12. Following the sale, the insider directly owned 7,007 shares of the company's stock, valued at approximately $182,252.07. This represents a 22.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 192,991 shares of company stock worth $5,152,084 in the last three months. 5.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. ARCH Venture Management LLC purchased a new stake in shares of Maze Therapeutics in the 2nd quarter worth $122,983,582. Alphabet Inc. bought a new position in Maze Therapeutics in the 2nd quarter worth $41,435,000. TRV GP IV LLC bought a new position in Maze Therapeutics in the 2nd quarter worth $133,502,907. Frazier Life Sciences Management L.P. lifted its position in Maze Therapeutics by 10.2% during the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company's stock valued at $150,182,000 after purchasing an additional 465,641 shares in the last quarter. Finally, Jupiter Topco LLC purchased a new position in Maze Therapeutics during the second quarter valued at $101,764,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions.

Maze's pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.